Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study - Perez-Garcia, Jose Manuel; Gebhart, Geraldine; Borrego, Manuel Ruiz; Schmid, Peter; Marmé, Frederik; Prat, Aleix; Dalenc, Florence; Kerrou, Khaldoun; Colleoni, Marco; Braga, Sofía; Malfettone, Andrea; Sampayo-Cordero, Miguel; et al. (Future oncology, 2022)
Gesehen am 21.08.2023